Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Inclusion criteria

• aged 20 to 80 years
• men and women with coronary artery disease who had been treated with drug-eluting stent placement before > 12 months
• patients who had remained in a stable condition with a single antiplatelet agent, aspirin
• patients who did not show any sign or symptom of the worsening of their angina within the last six months that required a coronary artery intervention, a coronary artery bypass, or coronary angiography

Exclusion criteria

• Patients who were taking another antiplatelet or anticoagulant drug such as clopidogrel, warfarin, or cilostazol in addition to aspirin, unless they could withdraw from such other drug/s, in which case they could be enrolled in the study after a two-week wash-out period
• Patients who were suffering from drug abuse or alcohol addiction
• hypersensitivity to clopidogrel or aspirin
• severe liver disease (ALT or AST ≥ 10 times the upper normal limit)
• active hemorrhage such as gastro-intestinal ulcer or intracranial hemorrhage
• a high risk of bleeding (blood coagulation disorder, uncontrolled severe hypertension, active bleeding, or history of severe bleeding)
• pregnant or lactating women
• women with childbearing potential who were not using an appropriate contraception method
• had medical or mental contra-indications to the study treatment